Attached files
file | filename |
---|---|
8-K/A - FIRST CHINA PHARMACEUTICAL GROUP, INC. | v208453_8ka.htm |
EX-99.4 - FIRST CHINA PHARMACEUTICAL GROUP, INC. | v208453_ex99-4.htm |
EX-10.4 - FIRST CHINA PHARMACEUTICAL GROUP, INC. | v208453_ex10-4.htm |
EX-99.1C - FIRST CHINA PHARMACEUTICAL GROUP, INC. | v208453_ex99-1c.htm |
EX-99.1A - FIRST CHINA PHARMACEUTICAL GROUP, INC. | v208453_ex99-1a.htm |
Exhibit 99.1
(b)
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
PRO
FORMA CONSOLIDATEDFINANCIAL
STATEMENTS
FOR THE
SIX MONTHS ENDED JUNE 30, 2010
(Stated
in US Dollars)
(Unaudited)
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
INDEX TO
PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS
Pages
|
||
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
1
|
|
PRO
FORMA COMBINED BALANCE SHEETS
|
2
|
|
PRO FORMA CONSOLIDATED STATEMENTS
OF INCOME AND COMPREHENSIVE
INCOME
|
3
|
|
PRO
FORMA CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
|
4
|
|
PRO
FORMA CONSOLIDATED STATEMENTS OF CASH FLOWS
|
5
|
|
NOTES
TO THE PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS
|
6 -
18
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the
Board of Directors and Stockholders of
First
China Pharmaceutical Group Limited
We have
reviewed the accompanying pro forma consolidated balance sheets of First China
Pharmaceutical Group Limited (“the Company”) as of June 30, 2010, and the
related pro forma consolidated statement of operations and cash flows for the
six months ended June 30, 2010. These financial statements are the
responsibility of the Company’s management.
We
conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of pro forma
consolidated interim financial information consists principally of applying
analytical procedures and making inquiries of persons responsible for financial
and accounting matters. It is substantially less in scope than an
audit conducted in accordance with generally accepted auditing standards in the
United States, the objective of which is the expression of an opinion regarding
the financial statements taken as a whole. Accordingly, we do not
express such an opinion.
Based on
our review, we are not aware of any material modifications that should be made
to the accompanying pro forma consolidated financial statements for them to be
in conformity with accounting principles generally accepted in the United States
of America.
Parker
Randall CF (H.K.) CPA Limited
Certified
Public Accountants
Hong
Kong
November
19 2010
1
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
PRO
FORMA CONSOLIDATED BALANCE SHEETS
(Stated
in US Dollars)
(Unaudited)
At
|
At
|
|||||||||
June 30,
|
December 31,
|
|||||||||
Notes
|
2010
|
2009
|
||||||||
$
|
$
|
|||||||||
ASSETS
|
||||||||||
Current
Assets
|
||||||||||
Cash
and cash equivalents
|
19,414 | 37,752 | ||||||||
Restricted
cash
|
2(e)
|
- | 805,150 | |||||||
Due
from a related party
|
3
|
14,162,350 | 11,753,223 | |||||||
Inventories
|
4
|
5,908,464 | 2,926,335 | |||||||
Total
current assets
|
20,090,228 | 15,522,460 | ||||||||
Plant
and equipment, net
|
5
|
3,497 | 4,253 | |||||||
Intangible
assets, net
|
6
|
2,608 | 2,990 | |||||||
TOTAL
ASSETS
|
20,096,333 | 15,529,703 | ||||||||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
||||||||||
Current
Liabilities
|
||||||||||
Short-term
borrowings
|
7
|
859,677 | 729,427 | |||||||
Other
payable and accrued liabilities
|
8
|
10,480,234 | 7,971,681 | |||||||
Notes
payable
|
9
|
- | 313,654 | |||||||
Income
tax payable
|
2,265,720 | 1,750,611 | ||||||||
Total
Current Liabilities
|
13,605,631 | 10,765,373 | ||||||||
TOTAL
LIABILITIES
|
13,605,631 | 10,765,373 | ||||||||
COMMITMENTS
AND CONTINGENCIES
|
13
|
- | - | |||||||
STOCKHOLDERS’
EQUITY
|
||||||||||
Common
stock
|
10
|
|||||||||
Authorized, issued and
outstanding:
|
||||||||||
10,000
common shares, par value HK$1 per share
|
1,285 | 1,285 | ||||||||
Retained
earnings
|
6,454,592 | 4,776,852 | ||||||||
Accumulated
other comprehensive income
|
||||||||||
-
foreign currency translation adjustments
|
34,825 | (13,807 | ) | |||||||
TOTAL
STOCKHOLDER’S EQUITY
|
6,490,702 | 4,764,330 | ||||||||
TOTAL
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
20,096,333 | 15,529,703 |
See
accompanying notes to the financial statements
2
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
PRO
FORMA CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Stated
in US Dollars)
(Unaudited)
Three months ended
|
Six months ended
|
|||||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||||
Notes
|
2010
|
2009
|
2010
|
2009
|
||||||||||||||
$
|
$ |
$
|
$
|
|||||||||||||||
Net
sales
|
7,182,191 | 6,242,501 | 13,876,734 | 12,010,507 | ||||||||||||||
Costs
of sales
|
(5,931,643 | ) | (5,232,242 | ) | (11,442,368 | ) | (10,370,826 | ) | ||||||||||
Gross
profit
|
1,250,548 | 1,010,259 | 2,434,366 | 1,639,681 | ||||||||||||||
Selling
expenses
|
(4,592 | ) | (5,868 | ) | (8,859 | ) | (13,321 | ) | ||||||||||
Administrative
expenses
|
(38,165 | ) | (23,948 | ) | (78,251 | ) | (57,118 | ) | ||||||||||
Depreciation
and amortization
|
(721 | ) | (1,226 | ) | (1,196 | ) | (4,410 | ) | ||||||||||
Other
(losses)/gains-
|
||||||||||||||||||
Gain
from Bargain Purchase
|
- | - | - | 2,033,545 | ||||||||||||||
Other
operating expenses
|
(21,230 | ) | (4,671 | ) | (91,962 | ) | (7,457 | ) | ||||||||||
Income
from operations
|
1,185,840 | 974,546 | 2,254,098 | 3,590,920 | ||||||||||||||
Interest
income
|
3,722 | 5,379 | 5,083 | 7,121 | ||||||||||||||
Interest
expense
|
(12,071 | ) | - | (22,159 | ) | - | ||||||||||||
Income
before tax
|
1,177,491 | 979,925 | 2,237,022 | 3,598,041 | ||||||||||||||
Income
tax
|
12
|
(294,373 | ) | (244,981 | ) | (559,282 | ) | (391,124 | ) | |||||||||
Net
income
|
883,118 | 734,944 | 1,677,740 | 3,206,917 | ||||||||||||||
Other
comprehensive income
|
||||||||||||||||||
- foreign
currency translation adjustments
|
22,316 | 17,397 | 48,632 | 34,800 | ||||||||||||||
Comprehensive
income
|
905,434 | 752.341 | 1,726,372 | 3,241,717 |
See
accompanying notes to the financial statements
3
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
PRO
FORMA CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(Stated
in US Dollars)
Common stock
|
Additional
paid-in
|
Retained
|
Accumulated
other
comprehensive
|
||||||||||||||||||||||
Shares
|
Amount
|
capital
|
earnings
|
income
|
Total
|
||||||||||||||||||||
$ | $ | $ | $ | $ | |||||||||||||||||||||
Balance,
January 1, 2009
|
10,000 | 1,285 | - | - | - | 1,285 | |||||||||||||||||||
Net
income
|
- | - | - | 4,776,852 | - | 4,776,852 | |||||||||||||||||||
Foreign
currency translation adjustments
|
- | - | - | - | (13,807 | ) | (13,807 | ) | |||||||||||||||||
Balance,
June 30, 2009
|
10,000 | 1,285 | - | 4,776,852 | (13,807 | ) | 4,764,330 | ||||||||||||||||||
Balance,
January 1, 2010
|
10,000 | 1,285 | - | 4,776,852 | (13,807 | ) | 4,764,330 | ||||||||||||||||||
Net
income
|
- | - | - | 1,677,740 | - | 1,677,740 | |||||||||||||||||||
Foreign
currency translation adjustments
|
- | - | - | - | 48,632 | 48,632 | |||||||||||||||||||
Balance,
June 30, 2010
|
10,000 | 1,285 | - | 6,454,592 | 34,825 | 6,490,702 |
See
accompanying notes to the financial statements
4
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
PRO
FORMA CONSOLIDATED STATEMENT OF CASH FLOWS
(Stated
in US Dollars)
(Unaudited)
Six months ended
|
||||||||
June 30,
|
||||||||
2010
|
2009
|
|||||||
$ |
$
|
|||||||
Cash
Flows from Operating Activities
|
||||||||
Net
income
|
1,677,740 | 4,776,852 | ||||||
Adjustments
to reconcile net income to net cash
|
||||||||
provided
by operating activities:
|
||||||||
Depreciation
and amortization
|
1,196 | 4,444 | ||||||
Changes
in operating assets and liabilities:
|
||||||||
Due
from (to) a related party
|
(2,414,273 | ) | (1,404,652 | ) | ||||
Inventories
|
(2,988,125 | ) | (1,643,210 | ) | ||||
Other
payables and accrued liabilities
|
2,513,773 | 1,983,417 | ||||||
Notes
payable
|
(314,265 | ) | (543,584 | ) | ||||
Income
tax payable
|
516,185 | 390,260 | ||||||
Net
cash used in operating activities
|
(1,007,768 | ) | (42,546 | ) | ||||
Cash
Flows from Investing Activities
|
||||||||
Purchase
of plant and equipment
|
- | (2,892 | ) | |||||
Net
cash used in investing activities
|
- | (2,892 | ) | |||||
Cash
flows from financing activities
|
||||||||
New
borrowings raised
|
130,531 | - | ||||||
Decrease
(increase) in restricted cash
|
806,717 | (26,367 | ) | |||||
Net
cash provided by (used in) financing activities
|
937,248 | (26,367 | ) | |||||
Effect
of foreign currency translation on cash and cash
|
||||||||
equivalents
|
52,182 | (57 | ) | |||||
Net
decrease in cash and cash equivalents
|
(18,338 | ) | (71,862 | ) | ||||
Cash
and cash equivalents - beginning of period
|
37,752 | 80,857 | ||||||
Cash
and cash equivalents - end of period
|
19,414 | 8,995 | ||||||
Supplemental
disclosures for cash flow information:
|
||||||||
Cash
paid for:
|
||||||||
Interest
|
21,585 | - | ||||||
Income
taxes
|
- | - |
See
accompanying notes to the financial statements
5
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
1.
|
ORGANIZATION
AND PRINCIPAL ACTIVITIES
|
First
China Pharmaceutical Group limited (“the Company”) was incorporated in Hong Kong
on April 29, 2010 under the Companies Ordinance of Hong Kong. FCPG HK acts as
the holding company.
Kun Ming
Xin Yuan Tang Pharmacies Co. Ltd. (“XYT”) was established under the laws of the
People’s Republic of China (“PRC”) on November 12, 2002 with a paid-in capital
of RMB 2,000,000 as of September 30, 2010. The head office and warehouse are
located at Number 304, West Ren Min Road, Kunming City, Yunnan Province,
PRC.
On June
25, 2010, FCPG HK and XYT entered into an exchange of equity interests
agreement. Pursuant to the share exchange acquisition on June 25, 2010, FCPG HK
would pay RMB 2,000,000 to the predecessor shareholders of XYT, RMB 1,900,000 to
Mr. Wang and RMB 100,000 to Ms. Gong for acquiring all the share of XYT. The
transferring cash amount of RMB 2,000,000 was the amount of capital contributed
of XYT and had been negotiated among FCPG HK, Mr. Wang and Ms Gong. FCPG HK, the
entity transferred the cash, has been identified the acquirer. FCPG HK paying
US$300,000 (2,000,000RMB) to acquire all share capital of XYT, of which became
FCPG HK’s wholly owned subsidiary.
The
Company and the Subsidiaries (collectively the “Group”) are principally engaged
in drug logistics and distribution in Yunnan Province, China through drug
stores, medical clinics and hospitals.
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
|
(a)
|
Basis
of Preparation and Presentation
|
At the
time of acquisition of FCPG-HK acquires XYT of PRC, the controlling shareholder
of FCPG-HK is the same before and after the acquisition of XYT, whereas the
acquisition is deemed to be completed on June 25, 2010, that is, without
material financial impact, to be taken as June 30, 2010. Therefore, for any
consolidated financial statements including both FCPG-HK. as the parent and XYT
as the subsidiary covering period on or before June 30, 2010, can only be
prepared in the form of 'pro-forma', that is, 'as if' the business combination
has been occurred in the basis period prepared.
The pro
forma consolidated statements of income and comprehensive income and pro form
consolidated statements of cash flows of the companies have been prepared as if
the current group structure had been in existence throughout the periods for the
six months ended June 30, 2010 and June 30, 2009.
The pro
forma consolidated balance sheets of the Group as at June 30, 2010 and December
31, 2009 have been prepared to present the assets and liabilities of the Group
as at the respective dates as if the current group structure had been in
existence as at those dates.
The
Group’s pro forma consolidated financial statements have been prepared in
accordance with generally accepted accounting principles in the United States of
America for illustrative of interim consolidated financial
information. Accordingly, they do not include all the information and
notes necessary for comprehensive consolidated financial
statements.
6
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
In the
opinion of the management of the Group, all adjustments, which are of a normal
recurring nature, necessary for a fair statement of the results for the
six-month periods have been made. Results for the interim period
presented are not necessarily indicative of the results that might be expected
for the entire fiscal year.
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(b)
|
Use
of Estimates
|
In
preparing of the financial statements in conformity with accounting principles
generally accepted in the United States of America, management makes estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the dates of the financial
statements, as well as the reported amounts of revenues and expenses during the
reporting periods. These accounts and estimates include, but are not
limited to, the valuation of due from a related party, inventories and the
estimation on useful lives of plant and machinery and intangible assets. Actual
results could differ from those estimates.
(c)
|
Concentration
of Credit Risk
|
Financial
instruments that potentially expose the Group to concentrations of credit risk
consist primarily of cash and cash equivalents, restricted cash and due from a
related party. The Group places its cash with financial institutions with
high-credit ratings and quality. The Group conducts periodic reviews of the
related party financial conditions and payment practices.
No single
external customer exceeded 10% of the Group’s total revenue for the periods
presented.
The Group
relies on supplies from numerous vendors. The Group had one vendor that
accounted for approximately 22% and 15% of total purchases for the six months
ended June 30, 2010 and 2009 respectively.
(d)
|
Cash
and Cash Equivalents
|
The Group
considers all highly liquid investments with initial maturities of three months
or less to be cash equivalents. The Group maintains bank accounts in the PRC
only.
(e)
|
Restricted
Cash
|
Deposits
in banks for securities of notes payable that are restricted in use are
classified as restricted cash under current assets.
(f)
|
Trade
and Other Receivables
|
Trade and
other receivables are recognised initially at fair value and subsequently
measured at amortised cost using the effective interest method, less allowance
for impairment. An allowance for impairment of trade and other receivables is
established when there is objective evidence that the Group will not be able to
collect all amounts due according to the original terms of receivables. The
amount of the allowance is the difference between the receivable’s carrying
amount and the present value of estimated future cash flows, discounted at the
effective interest rate computed at initial recognition. The amount of the
allowance is recognised in the statement of income and comprehensive
income.
7
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(g)
|
Inventories
|
Inventories
are stated at the lower of cost and net realisable value. Cost is determined
using the weighted average basis. The cost of inventories, principally
comprising purchase cost and other costs incurred in bringing the inventories to
their present location and condition. Net realisable value is the estimated
selling price in the ordinary course of business, less the estimated costs of
completion and the estimated costs necessary to make the sale.
During
the reporting periods, the Group did not make any allowance for slow-moving or
defective inventories.
(h)
|
Plant
and Equipment
|
Plant and
equipment are stated at cost less depreciation and accumulated impairment loss.
Cost represents the purchase price of the asset and other costs incurred to
bring the asset into its existing use. Maintenance, repairs and betterments,
including replacement of minor items, are charged to expense; major additions to
physical properties are capitalized.
Depreciation
of plant and equipment is calculated to written off the cost, less their
estimated residual value, if any, using the straight-line method over their
estimated useful lives. The principal annual rates are as follows:
Office
equipment
|
33 | 1/3% | |
Other
equipment
|
20 | % | |
Motor
vehicles
|
25 | % |
(i)
|
Intangible
Assets
|
Intangible
assets are stated at cost less amortization and accumulated impairment loss. The
intangible assets of the Group represent software in used. The
intangible assets are amortized over their estimated useful lives of 10 years
using the straight-line method.
(j)
|
Impairment
of Long-lived Assets
|
Long-lived
assets are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of the assets may not be recoverable. The
Group recognizes impairment of long-lived assets in the event that the net book
values of such assets exceed the future undiscounted cashflows attributable to
such assets. No impairment of long-lived assets was recognized for any of the
periods presented.
(k)
|
Revenue
Recognition
|
Revenue
from sales of the Group’s products is recognized when the significant risks and
rewards of ownership have been transferred to the buyer at the time of delivery
and the sales price is fixed or determinable and collection is reasonably
assured.
8
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(l)
|
Advertising
expenses
|
Advertising
expenses are charged to expense as incurred. No advertising expenses were
incurred during the six months ended June 30, 2010 and 2009.
(m)
|
Income
taxes
|
The Group
uses the asset and liability method of accounting for income taxes pursuant to
SFAS No. 109 “Accounting for Income Taxes”. Under the asset and
liability method of SFAS 109, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to temporary differences between
the financial statements carrying amounts of existing assets and liabilities and
loss carryforwards and their respective tax bases. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to
be recovered or settled.
(n)
|
Comprehensive
Income
|
Comprehensive
income is defined to include all changes in equity except those resulting from
investments by owners and distributions to owners. Among other
disclosures, all items that are required to be recognized under current
accounting standards as components of comprehensive income are required to be
reported in a financial statement that is presented with the same prominence as
other financial statements. The Group’s current component of other comprehensive
income is the foreign currency translation adjustments.
9
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(o)
|
Foreign
Currency Translation
|
The Group
maintains its financial statements in the functional currency. The functional
currency of the Company is Hong Kong dollar (“HK$”) and the functional currency
of Xin Yun Tang is the Renminbi (“RMB”). Monetary assets and liabilities
denominated in currencies other than the functional currency are translated into
the functional currency at rates of exchange prevailing at the balance sheet
dates. Transactions denominated in currencies other than the functional currency
are translated into the functional currency at the exchanges rates prevailing at
the dates of the transaction. Exchange gains or losses arising from foreign
currency transactions are included in the determination of net income for the
respective periods.
For
financial reporting purposes, the financial statements of the Company and Xin
Yun Tang which are prepared using the functional currency have been translated
into United States dollars (“US$”). Assets and liabilities are translated at the
exchange rates at the balance sheet dates and revenue and expenses are
translated at the average exchange rates and stockholders’ equity is translated
at historical exchange rates. Any translation adjustments resulting are not
included in determining net income but are included in foreign exchange
adjustment to other comprehensive income, a component of stockholders’
equity.
Exchange
rates applied for the foreign currency translation during the period are as
follows:
HKD$1
to RMB
|
2010
|
2009
|
||||||
Closing
rate
|
0.8724 | 0.8819 | ||||||
Average
rate
|
0.8765 | 0.9092 |
US$1
to HKD
|
2010
|
2009
|
||||||
Closing
rate
|
7.7853 | 7.7850 | ||||||
Average
rate
|
7.7699 | 7.7539 |
HK$ is
pegged to US$ and hence there is no significant translation adjustment impact on
these financial statements.
RMB is
not freely convertible into foreign currency and all foreign exchange
transactions must take place through authorized institutions. No representation
is made that the RMB amounts could have been, or could be, converted into US$ at
the rates used in translation.
10
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(p)
|
Financial
instruments
|
The
carrying amounts of all financial instruments approximate fair value. The
carrying amounts of cash and cash equivalents, restricted cash, due from (to) a
related party, notes payable, other payable and accrued liabilities and income
tax payable approximate their fair values due to the short-term nature of these
items. The carrying amounts of short-term borrowings approximate the fair value
based on the Group’s expected borrowing rate for debt with similar remaining
maturities and comparable risk.
It is
management’s opinion that the Group is not exposed to significant interest,
price or credit risks arising from these financial instruments.
(q)
|
Recent
Accounting Pronouncements
|
In April
2009, the FASB issued FSP 157-4 “Determining Fair Value When the Volume and
Level of Activity for the Asset or Liability Have Significantly Decreased and
Identifying Transactions That Are Not Orderly”. FSP 157-4 provides additional
guidance for estimating fair value in accordance with SFAS 157 when the volume
and level of activity for the asset or liability have significantly decreased.
FSP 157-4 also includes guidance on identifying circumstances that indicate a
transaction is not orderly. FSP 157-4 is effective for interim and annual
reporting periods ending after June 15, 2009, with early adoption permitted for
periods ending after March 15, 2009. FSP 157-4 does not require disclosures for
earlier periods presented for comparative purposes at initial adoption. In
periods after initial adoption, FSP 157-4 requires comparative disclosures only
for periods ending after initial adoption.
In May
2009, the FASB issued FSP SFAS 165 “Subsequent Events”. The objective of this
Statement is to establish general standards of accounting for and disclosures of
events that occur after the balance sheet date but before financial statements
are issued or are available to be issued. SFAS 165 is effective for the interim
and annual periods ending after June 15, 2009, which is now codified as FASB ASC
855 “Subsequent Events”. The adoption of FASB ASC 855 did not have a material
impact on the Company’s financial position, results of operations and cash
flows. Effective February 24, 2010, the Company adopted Accounting Standards
Update (“ASU”) No. 2010-09, “Subsequent Events (Topic 855): Amendments to
Certain Recognition and Disclosure Requirements”, which removes the requirement
to disclose the date through which subsequent events have been
evaluated.
In June
2009, the FASB issued SFAS No. 166 “Accounting for Transfers of Financial Assets
– an amendment of FASB Statement No. 140”. This statement is intended to improve
the relevance, representational faithfulness, and comparability of the
information that a reporting entity provides in its financial reports about a
transfer of financial assets; the effects of a transfer on its financial
position, financial performance, and cash flows; and a transferor’s continuing
involvement in transferred financial assets. This Statement must be applied as
of the beginning of each reporting entity’s first annual reporting period that
begins after November 15, 2009, and is required to be adopted by the Company in
the first quarter of fiscal year 2011. Earlier application is prohibited. This
Statement must be applied to transfers occurring on or after the effective
date.
11
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(q)
|
Recent
Accounting Pronouncements (cont’d)
|
In June
2009, the FASB issued SFAS No.167, “Amendments to FASB Interpretation No.46(R)”,
which is codified as ASC 810. ASC 810 amends FASB Interpretation No.46(R),
“Variable Interest Entities” for determining whether an entity is a variable
interest entity (“VIE”) and requires an enterprise to perform an analysis to
determine whether the enterprise’s variable interest or interests give it a
controlling financial interest in a VIE. Under ASC 810, an enterprise has a
controlling financial interest when it has a) the power to direct the activities
of a VIE that most significantly impact the entity’s economic performance and b)
the obligation to absorb losses of the entity or the right to receive benefits
from the entity that could potentially be significant to the VIE. ASC 810 also
requires an enterprise to assess whether it has an implicit financial
responsibility to ensure that a VIE operates as designed when determining
whether it has power to direct the activities of the VIE that most significantly
impact the entity’s economic performance.
ASC 810
also requires ongoing assessments of whether an enterprise is the primary
beneficiary of a VIE, requires enhanced disclosures and eliminates the scope
exclusion for qualifying special-purpose entities. ASC 810 shall be effective as
of the beginning of each reporting entity’s first annual reporting period that
begins after November 15, 2009, for interim periods within that first annual
reporting period, and for interim and annual reporting periods thereafter.
Earlier application is prohibited. ASC 810 is effective for the Company in the
first quarter of fiscal 2011.
In June
2009, the FASB issued SFAS 168, “The FASB Accounting Standards CodificationTM and the
Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB
Statement No 162”, which supersedes all existing non-SEC accounting and
reporting standards. The codification does not change GAAP but rather organizes
it into a new hierarchy with two levels: authoritative and non-authoritative.
All authoritative GAAP carries equal weight and is organized in a topical
structure.
In August
2009, the FASB issued Accounting Standards Update (“ASU”) No. 2009-05,
“Measuring Liabilities at Fair Value”, which is codified as ASC 820, “Fair Value
Measurements and Disclosures”. This Update provides amendments to ASC 820-10,
Fair Value Measurements and Disclosures –Overall, for the fair value measurement
of liabilities. This Update provides clarification that in circumstances in
which a quoted price in an active market for the identical liability is not
available, a reporting entity is required to measure fair value using a
valuation technique that uses the quoted price of the identical liability when
traded as an asset, quoted prices for similar liabilities or similar liabilities
when traded as assets, or that is consistent with the principles of ASC 820. The
amendments in this Update also clarify that when estimating the fair value of a
liability, a reporting entity is not required to include a separate input or
adjustment to other inputs relating to the existence of a restriction that
prevents transfer of the liability.
12
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONT’D)
|
(q)
|
Recent
Accounting Pronouncements (cont’d)
|
The
amendments in this Update also clarify that both a quoted price in an active
market for the identical liability at the measurement date and the quoted price
for the identical liability when traded as an asset in an active market when no
adjustments to the quoted price of the assets are required are Level 1 fair
value measurements. ASC 820 is effective for the first reporting period
(including interim periods) beginning after August 28, 2009.
In
September 2009, the FASB issued ASU No. 2009-06, “Income Taxes (Topic
740)—Implementation Guidance on Accounting for Uncertainty in Income Taxes and
Disclosure Amendments for Nonpublic Entities”, and it provides implementation
guidance on accounting for uncertainty in income taxes effective for interim and
annual reporting period ending on or after September 15, 2009.
In
December 2009, the FASB issued ASU No. 2009-17, “Improvements to Financial
Reporting by Enterprises Involved with Variable Interest Entities (“ASU
2009-17”)”. ASU 2009-17 amends the variable-interest entity guidance in FASB ASC
810-10-05-8 to clarify the accounting treatment for legal entities in which
equity investors do not have sufficient equity at risk for the entity to finance
its activities without financial support. ASU 2009-17 shall be effective as of
the beginning of each reporting entity’s first annual reporting period that
begins after November 15, 2009. ASU 2009-17 is effective for the Company in the
first quarter of fiscal 2011.
The Group
does not anticipate that the adoption of the above recent accounting
pronouncements will have a material impact on these financial
statements.
3.
|
DUE
FROM A RELATED PARTY
|
The
amount due from (to) a related party, Mr. Zhen Jiang Wang who is the major
equity holder of XYT as of June 30, 2010, is interest free, unsecured and
repayable on demand.
Refers to
SAB Topics 4E and 4G, the scenario and background described therein, which is
related to capital contribution or unpaid equity of an enterprises, is not
applicable in the item as presented under 'Amount due from Shareholder' as
presented in the financial statements due to the different nature and background
that give rise to such amount.
The
amount as appeared in an item " Amount due from shareholders’ here, in fact
represents the situation where the shareholder of XYT, Mr. Wang, has collected
certain trade receivables on behalf of the subsidiaries of XYT, while XYT
conducts business in China, whereas also Mr. Wang would settle on behalf of XYT,
for certain trade payables. Therefore, we suppose the satiation is not the same
as any capital contribution commitment or unpaid subscription as outlined by SAB
4E or 4G. XYTwould have the control measures to manage and eliminate such amount
being owed by shareholder to XYT as part of the corporate
governance.
XYT will
settle such “Amount due from shareholders” by distribute dividends or authorize
Mr. Wang to make prepayment to the suppliers.
13
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
4.
|
INVENTORY
|
At
|
At
|
||||||
June 30,
|
December 31,
|
||||||
2010
|
2009
|
||||||
$ |
$
|
||||||
Finished
goods
|
5,908,464
|
2,926,335 |
5.
|
PLANT
AND EQUIPMENT, NET
|
At
|
At
|
|||||||
June 30,
|
December 31,
|
|||||||
2010
|
2009
|
|||||||
$ |
$
|
|||||||
Cost
|
||||||||
Office
equipment
|
9,939 | 9,887 | ||||||
Other
equipment
|
29,874 | 29,717 | ||||||
Motor
vehicles
|
21,814 | 21,459 | ||||||
Total
|
61,627 | 61,063 | ||||||
Accumulated
depreciation
|
(58,130 | ) | (56,810 | ) | ||||
Property,
plant and equipment, net
|
3,497 | 4,253 |
Depreciation
charged for the six months ended June 30, 2010 and 2009 were $1,090 and $3,801
respectively.
6.
|
INTANGIBLE
ASSET, NET
|
At
|
At
|
|||||||
June 30,
|
December 31,
|
|||||||
2010
|
2009
|
|||||||
$ |
$
|
|||||||
|
||||||||
Cost
|
8,218 | 8,161 | ||||||
Accumulated
amortization
|
(5,610 | ) | (5,171 | ) | ||||
Intangible
asset, net
|
2,608 | 2,990 |
Amortization
recognized in the administrative expenses for the six months ended June 30, 2010
and 2009 were $106 and $609 respectively.
14
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
6.
|
INTANGIBLE
ASSET, NET (CONT’D)
|
The
estimated aggregate amortization expenses for each of the five succeeding years
are as follows:
Twelve
months ending June 30
|
$
|
|||
2011
|
817 | |||
2012
|
817 | |||
2013
|
688 | |||
2014
|
163 | |||
2015
and thereafter
|
123 | |||
2,608 |
7.
|
SHORT-TERM
BORROWINGS
|
The
details of short-term borrowings as of June 30, 2010 are as
follows:
Nature
|
Annual
Interest
Rate
|
Period
|
Outstanding
loan
amount
|
Collateral
|
|||||||||
$ | |||||||||||||
Bank
loan
|
7.97 | % |
27/04/2010 – 26/04/2011
|
123,518 | N/A | ||||||||
Bank
loan
|
5.31 | % |
07/12/2009 – 06/12/2010
|
736,279 | N/A | ||||||||
859,797 |
Interest
expense charged to operations for the short-term borrowings was $21,585 for the
six months ended June 30, 2010. There was no default of bank loan or interest
payments during the period.
8.
|
OTHER
PAYABLE AND ACCRUED LIABILITIES
|
At
|
At
|
|||||||
June 30,
|
December 31,
|
|||||||
2010
|
2009
|
|||||||
$ |
$
|
|||||||
Rental
payable
|
59,161 | 58,223 | ||||||
Other
payables
|
442,375 | 437,439 | ||||||
Staff
costs payables
|
226,394 | 132,581 | ||||||
Value
added tax payable
|
9,751,413 | 7,342,174 | ||||||
Other
accrued expenses
|
891 | 1,264 | ||||||
10,480,234 | 7,971,681 |
15
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
9.
|
NOTES
PAYABLE
|
The notes
payable which were issued by the Group with bank guarantees are secured by the
restricted cash.
10.
|
SHARE
CAPITAL
|
On the
date of incorporation, the Group issued 10,000 common stock of HK$1 each to the
subscriber for initial working capital.
11.
|
PENSION
PLANS
|
The Group
contributes on a monthly basis to various defined contribution retirement
benefit plans organized by relevant municipal and provincial governments in the
PRC. The municipal and provincial governments undertake to assume the
retirement benefit obligations payable to all existing and future retired
employees under these plans and the Group has no further obligation for
post-retirement benefits beyond the contributions made. Contributions to these
plans are expensed as incurred.
During
the six months ended June 30, 2010 and 2009, total pension costs recognized were
$1,965 and $1,056 respectively.
12.
|
OTHER
(LOSSES)/GAINS
|
Pursuant
to ASC-805-30-25-2, bargain purchases occur if the acquisition-date amounts of
the identifiable net assets acquired, excluding goodwill, exceed the sum of (i)
the value of consideration transferred, (ii) the value of any non-controlling
interest in the acquiree, and (iii) the fair value of any previously held equity
interest in the acquiree. The Standards require the recognition of a gain for a
bargain purchase [ASC 805-30-25-2; IFRS 3R.34]. The Boards believe that a
bargain purchase represents an economic gain, which should be immediately
recognised by the acquirer in earnings [profit or loss] [FAS
141(R).B372;].
The other
gains of the Group represents gain from bargain purchase which arisen “as if” on
Jan 1st, 2009, when the company acquired XYT for around US$ 300,000 (2,000,000
RMB), the value of consideration transferred, in the pro forma financial
statement. The fair value of the identifiable net assets acquired was $US
2,321,100. XYT became FCPG HK’s wholly owned subsidiary.
FCPG HK,
the acquirer reassess whether all of the assets acquired and liabilities assumed
have been identified and recognised, including any additional assets and
liabilities not previously identified or recognized in the acquisition
accounting. Once completed, the acquirer should review the procedures used to
measure the following items:
•
|
Identifiable
assets acquired and liabilities
assumed
|
•
|
Non-controlling
interest in the acquiree,
|
•
|
Acquirer’s
previously held equity interest in the acquiree, if
any
|
•
|
Consideration
transferred [ASC 805-30-30-5]
|
16
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
Consideration
transferred is generally measured at fair value. Consideration transferred is
the sum of the acquisition-date fair values of the assets transferred, the
liabilities incurred by the acquirer to the former owners of the acquiree, and
the equity interests issued by the acquirer to the former owners of the acquiree
(except for the measurement of share-based payment awards, see BCG
2.6.3.1).
An
impairment test had been implemented on the identifiable assets, mainly in our
case in XYT refers to the Pharmaceuticals inventories and due from related
party. We found there is no impairment on the inventories. And the amount of due
from related party is existed and accurate. The fair value of the identifiable
net assets acquired retained $US 2,321,100. There are neither any
non-controlling interests nor any previously held equity interest in the
acquiree.
The
consideration transferred amount of US$300,000 (2,000,000RMB) had been
negotiated among Mr. Wang, who held 95% share of XYT, Ms. Gong, who held 5%
share of XYT and FCPG HK.
After
assessing whether all the identifiable net assets have been identified and
recognized and reviewing the measurement of (i) those identifiable net assets,
and (ii) the consideration transferred and review the procedures used to
measure, FCPG HK did not adjust the value of the identifiable net assets
acquired to US$ 300,000 (2,000,000 RMB). Hence a bargain purchase of $US
2,033,545 had been recognize.
13.
|
INCOME
TAX
|
Income
tax expense for the six months ended June 30, 2010 and 2009 represents the
provision for current income tax expenses in the PRC.
A
reconciliation of the tax expense applicable to income before tax using the
statutory rate of 25% to the tax expense at the effective tax rate is as
follows:
Six months ended June 30, |
|
|||||||
2010
|
2009
|
|||||||
$ |
$
|
|||||||
Income
before tax
|
2,237,022 | 3,598,041 | ||||||
Tax
at the statutory rate
|
559,255 | 391,124 | ||||||
Expenses
not deductible for tax
|
17 | - | ||||||
Others
|
10 | - | ||||||
Effective
income tax expenses
|
559,282 | 391,124 |
No
provision for Hong Kong profits tax has been made as the Group did not generate
any assessable profits arising in Hong Kong during the periods.
There was
no unprovided deferred tax in respect of the periods and as at the balance sheet
dates.
17
FIRST
CHINA PHARMACEUTICAL GROUP LIMITED
NOTES
TO PRO FORMA COMBINED FINANCIAL STATEMENTS
(Stated
in US Dollars)
(Unaudited)
14.
|
COMMITMENTS
AND CONTINGENCIES
|
The Group
leases the office and warehouse under non-cancelable operating lease agreement
that expire in 2018.
15.
|
RELATED
PARTY TRANSACTIONS
|
Apart
from the transactions and balances disclosed elsewhere in the financial
statements, the Group had no material transactions with its related parties
during the periods presented.
16.
|
SEGMENT
INFORMATION
|
No
segment information is disclosed as the Group is engaged in the sales of Chinese
patent drug, antibiotics, bio-chemicals, chemical preparations and biological.
The nature of the products, the type of their customers and their distribution
methods are substantially similar. The Group operates in a single segment in the
PRC. All of long-lived assets are located in the PRC.
17.
|
POST
BALANCE SHEET EVENTS
|
Pursuant
to a share sale agreement on July 5, 2010, the sole shareholder of FCPG HK
Group, Mr. Douglas Billingsley will sale all of his shares to Mr. Zhen Jiang
Wang for considerations. Mr. Zhen Jiang Wang will then become the sole
shareholder of the FCPG HK Group, among which are FCPG HK, and XYT.
On August
23, 2010, the FCPG HK Group will enter into a voluntary share exchange
transaction with First China Pharmaceutical Group, Inc., a Nevada corporation
(“FCPG-US”), a Nevada corporation which stocks trade on the Over-The-Counter
Bulletin Board pursuant to a Share Exchange Agreement (the “Exchange Agreement”)
by and among FCPG-US, on the one hand, and the FCPG HK Group, XYT and Mr. Zhen
Jiang Wang (the “Selling Shareholder”), on the other hand.
Following
the Exchange Transaction, the Selling Shareholder will own approximately 25% of
FCPG-US’s issued and outstanding common stock, the FCPG HK Group will become
FCPG-US’s wholly owned subsidiaries, and FCPG-US will acquire the business and
operations of the Group.
18